Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)

Next Previous
X
Search
Trial Profile

HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab-deruxtecan (Primary)
  • Indications Cancer
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic
  • Acronyms HER2-PREDICT

    • Most Recent Events

    • 23 Jan 2023 Planned End Date changed from 15 Dec 2023 to 15 Dec 2024.
    • 23 Jan 2023 Planned primary completion date changed from 15 Dec 2022 to 15 Dec 2023.
    • 10 Dec 2021 Trial design, presented at the 44th Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top